SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mahasen Abdel-Rahman, Yasmin Saad, Maissa El-Raziky, Naglaa Zayed, Wafaa El-Akel, Mohamed Said, Mohamed El-Beshlawy, Gamal Esmat, Hepatitis C genotype 4 with normal transaminases: Correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients, Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 5, 479

    CrossRef

  2. 2
    Naoko Tsubouchi, Hirofumi Uto, Kotaro Kumagai, Fumisato Sasaki, Shuji Kanmura, Masatsugu Numata, Akihiro Moriuchi, Makoto Oketani, Akio Ido, Katsuhiro Hayashi, Kazunori Kusumoto, Kazuya Shimoda, Sherri O. Stuver, Hirohito Tsubouchi, Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study, Hepatology Research, 2013, 43, 11
  3. You have free access to this content3
    G. Nunnari, M. R. Pinzone, B. Cacopardo, Lack of clinical and histological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up, Journal of Viral Hepatitis, 2013, 20, 4
  4. 4
    Hirofumi Uto, Seiich Mawatari, Kotaro Kumagai, Akio Ido, Hirohito Tsubouchi, Clinical Features of Hepatitis C Virus Carriers With Persistently normal Alanine Aminotransferase Levels, Hepatitis Monthly, 2012, 12, 2, 77

    CrossRef

  5. 5
    Kuo-Chih Tseng, Yun-Che Ho, Yu-Hsi Hsieh, Ning-Sheng Lai, Zhi-Hong Wen, Chin Li, Shu-Fen Wu, Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C, Journal of Gastroenterology, 2012, 47, 7, 823

    CrossRef

  6. 6
    C. Puoti, R. Guarisco, L. Spilabotti, L. Bellis, O. Mitidieri Costanza, O. Dell’ Unto, M. G. Elmo, Should we treat HCV carriers with normal ALT levels? The ‘5Ws’ dilemma, Journal of Viral Hepatitis, 2012, 19, 4
  7. 7
    Geilan A. Mahmoud, Hania S. Zayed, Mai M. Sherif, Mervat M. Mostafa, Characteristics of rheumatoid arthritis patients with concomitant hepatitis C virus infection, The Egyptian Rheumatologist, 2011, 33, 3, 139

    CrossRef

  8. 8
    Yaron Ilan, A fourth dimension in decision making in hepatology, Hepatology Research, 2010, 40, 12
  9. 9
    I. Maida, L. Martin-Carbonero, G. Sotgiu, E. Vispo, P. Barreiro, J. Gonzalez-Lahoz, V. Soriano, Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes, Journal of Viral Hepatitis, 2010, 17, 12
  10. 10
    Claudio Puoti, Lia Bellis, Riccardo Guarisco, Orlando Dell' Unto, Lucia Spilabotti, Olga Mitidieri Costanza, HCV carriers with normal alanine aminotransferase levels: Healthy persons or severely ill patients?, European Journal of Internal Medicine, 2010, 21, 2, 57

    CrossRef

  11. 11
    Rong-Ze Yang, Soohyun Park, William J. Reagan, Rick Goldstein, Shao Zhong, Michael Lawton, Francis Rajamohan, Kun Qian, Li Liu, Da-Wei Gong, Alanine aminotransferase isoenzymes: Molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity, Hepatology, 2009, 49, 2
  12. 12
    Gadi Lalazar, Yaron Ilan, Assessment of liver function in acute or chronic liver disease by the methacetin breath test: a tool for decision making in clinical hepatology, Journal of Breath Research, 2009, 3, 4, 047001

    CrossRef

  13. 13
    I. Itose, T. Kanto, N. Kakita, S. Takebe, M. Inoue, K. Higashitani, M. Miyazaki, H. Miyatake, M. Sakakibara, N. Hiramatsu, T. Takehara, A. Kasahara, N. Hayashi, Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis, Journal of Viral Hepatitis, 2009, 16, 12
  14. 14
    Vincenza Calvaruso, Antonio Craxì, Implication of normal liver enzymes in liver disease, Journal of Viral Hepatitis, 2009, 16, 8
  15. 15
    G. Sroczynski, E. Esteban, A. Conrads-Frank, R. Schwarzer, N. Muhlberger, D. Wright, S. Zeuzem, U. Siebert, Long-term effectiveness and cost-effectiveness of screening for Hepatitis C virus infection, The European Journal of Public Health, 2009, 19, 3, 245

    CrossRef

  16. 16
    Takashi Kumada, Hidenori Toyoda, Seiki Kiriyama, Yasuhiro Sone, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Hiroyuki Atsumi, Makiko Takagi, Satoshi Nakano, Takahiro Arakawa, Masashi Fujimori, Long-term follow-up of patients with hepatitis C with a normal alanine aminotransferase, Journal of Medical Virology, 2009, 81, 3
  17. 17
    Teruo Miyazaki, Akira Honda, Tadashi Ikegami, Takashi Hara, Yoshifumi Saitoh, Takeshi Hirayama, Mikio Doy, Yasushi Matsuzaki, The associated markers and their limitations for the primary screening of HCV carriers in public health examination, Hepatology Research, 2009, 39, 7
  18. 18
    G. Lalazar, O. Pappo, T. Hershcovici, T. Hadjaj, M. Shubi, H. Ohana, N. Hemed, Y. Ilan, A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT, Journal of Viral Hepatitis, 2008, 15, 10
  19. 19
    Takeshi Okanoue, Yoshito Itoh, Masahito Minami, Hiroaki Hashimoto, Kohichiro Yasui, Hiroshi Yotsuyanagi, Tetsuo Takehara, Takashi Kumada, Eiji Tanaka, Shuhei Nishiguchi, Namiki Izumi, Michio Sata, Morikazu Onji, Gotaro Yamada, Kiwamu Okita, Hiromitsu Kumada, Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts, Hepatology Research, 2008, 38, 1
  20. 20
    G. Sebastiani, A. Vario, M. Guido, A. Alberti, Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases, Journal of Viral Hepatitis, 2008, 15, 3
  21. 21
    Hirofumi Uto, Joji Kurogi, Yuka Takahama, Kazunori Kusumoto, Katsuhiro Hayashi, Akio Ido, Michinori Kohara, Sherri O Stuver, Akihiro Moriuchi, Susumu Hasegawa, Makoto Oketani, Hirohito Tsubouchi, Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan, Journal of Gastroenterology, 2007, 42, 8, 673

    CrossRef

  22. 22
    Patrick Marcellin, L’hépatite C en 2007 « Des progrès. Peut-on mieux faire… », Gastroentérologie Clinique et Biologique, 2007, 31, 8-9, 3

    CrossRef

  23. 23
    Ming-Lung Yu, Chia-Yen Dai, Li-Po Lee, Nei-Jen Hou, Ming-Yen Hsieh, Jee-Fu Huang, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Wan-Long Chuang, A 24-week course of high-dose interferon-α plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels, Liver International, 2006, 26, 10
  24. 24
    J. Chaves, A. Huen, C. Bueso-Ramos, A. Safdar, S. Vadhan-Raj, Aerosolized Ribavirin--Induced Reversible Hepatotoxicity in a Hematopoietic Stem Cell Transplant Recipient with Hodgkin Lymphoma, Clinical Infectious Diseases, 2006, 42, 8, e72

    CrossRef

  25. 25
    Norio Hayashi, Tetsuo Takehara, Antiviral therapy for chronic hepatitis C: past, present, and future, Journal of Gastroenterology, 2006, 41, 1, 17

    CrossRef

  26. 26
    Sangik Oh, Nezam H. Afdhal, Antiviral Therapy for Treatment Naïve Patients with Hepatitis C Virus, Infectious Disease Clinics of North America, 2006, 20, 1, 99

    CrossRef

  27. 27
    Mitchell L. Shiffman, Moisés Diago, Albert Tran, Paul Pockros, Robert Reindollar, Daniele Prati, Maribel Rodríguez–Torres, Pilar Lardelli, Steven Blotner, Stefan Zeuzem, Chronic Hepatitis C in Patients With Persistently Normal Alanine Transaminase Levels, Clinical Gastroenterology and Hepatology, 2006, 4, 5, 645

    CrossRef

  28. 28
    Stephen A. Harrison, HCV therapy in 2006: Down with ALT levels, in with awareness of co-existent metabolic syndrome, Journal of Hepatology, 2006, 44, 4, 624

    CrossRef

  29. 29
    Matilde Sanchez-Conde, Juan Berenguer, Pilar Miralles, Federico Alvarez, Juan Carlos Lopez, Jaime Cosin, Catalan Pilar, Margarita Ramirez, Isabel Gutierrez, Emilio Alvarez, Liver Biopsy Findings for HIV-Infected Patients with Chronic Hepatitis C and Persistently Normal Levels of Alanine Aminotransferase, Clinical Infectious Diseases, 2006, 43, 5, 640

    CrossRef

  30. 30
    Chen-Hua Liu, Jou-Wei Lin, Feng-Chiao Tsai, Pei-Ming Yang, Ming-Yang Lai, Jun-Herng Chen, Jia-Horng Kao, Ding-Shinn Chen, Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases, Liver International, 2006, 26, 9
  31. 31
    S. ZEUZEM, A. ALBERTI, W. ROSENBERG, P. MARCELLIN, M. DIAGO, F. NEGRO, D. PRATI, C. PUOTI, S. K. ROBERTS, M. L. SHIFFMAN, Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity, Alimentary Pharmacology & Therapeutics, 2006, 24, 8
  32. 32
    Giada Sebastiani, Alessandro Vario, Maria Guido, Franco Noventa, Mario Plebani, Roberta Pistis, Alessia Ferrari, Alfredo Alberti, Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C, Journal of Hepatology, 2006, 44, 4, 686

    CrossRef

  33. 33
    J. Hornberger, P. Farci, D. Prati, S. Zeuzem, J. Green, K. K. Patel, The economics of treating chronic hepatitis C patients with peginterferon α-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase, Journal of Viral Hepatitis, 2006, 13, 6
  34. 34
    Takeshi Okanoue, Akiko Makiyama, Mika Nakayama, Yoshio Sumida, Hironori Mitsuyoshi, Tomoki Nakajima, Kohichiroh Yasui, Masahito Minami, Yoshito Itoh, A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase, Journal of Hepatology, 2005, 43, 4, 599

    CrossRef

  35. 35
    Claudio Puoti, Lia Bellis, Francesca Martellino, Laura Durola, Lucia Spilabotti, Orlando Dell??Unto, Alessandra Galossi, Riccardo Guarisco, Occurrence of hepatocellular carcinoma in an apparently ???healthy??? HCV patient, European Journal of Gastroenterology & Hepatology, 2005, 17, 11, 1263

    CrossRef

  36. 36
    Alfredo Alberti, Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels, Journal of Hepatology, 2005, 42, 2, 266

    CrossRef

  37. 37
    R Peffault de Latour, T Asselah, V Lévy, C Scieux, A Devergie, P Ribaud, H Espérou, R Traineau, E Gluckman, D Valla, P Marcellin, G Socié, Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients, Bone Marrow Transplantation, 2005, 36, 8, 709

    CrossRef

  38. 38
    Cosimo Colletta, Carlo Smirne, Carlo Fabris, Pierluigi Toniutto, Rachele Rapetti, Rosalba Minisini, Mario Pirisi, Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases, Hepatology, 2005, 42, 4
  39. 39
    Sangik Oh, Nezam H. Afdhal, Antiviral therapy for treatment naı̈ve patients with hepatitis C virus, Gastroenterology Clinics of North America, 2004, 33, 3, 497

    CrossRef

  40. 40
    Bruce R. Bacon, Chronic Hepatitis C and Normal ALT: Considerations for Treatment, The American Journal of Gastroenterology, 2004, 99, 9, 1706

    CrossRef

  41. 41
    K. Rajender Reddy, CON: Most Patients Should Not be Treated, The American Journal of Gastroenterology, 2004, 99, 6, 973

    CrossRef

  42. 42
    Heike Bantel, Andreas Lügering, Jan Heidemann, Xandra Volkmann, Christopher Poremba, Christian P. Strassburg, Michael Peter Manns, Klaus Schulze-Osthoff, Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury, Hepatology, 2004, 40, 5
  43. 43
    Doris B. Strader, Teresa Wright, David L. Thomas, Leonard B. Seeff, Diagnosis, management, and treatment of hepatitis C, Hepatology, 2004, 39, 4
  44. 44
    Ira M. Jacobson, Furqaan Ahmed, Mark W Russo, Edward Lebovics, Douglas T. Dieterich, Stephen P. Esposito, Nancy Bach, Franklin Klion, Hillel Tobias, Louis Antignano, Robert S. Brown, David Gabbaizadeh, Jane Geders, Hulya Levendoglu, Interferon Alpha-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT, The American Journal of Gastroenterology, 2004, 99, 9, 1700

    CrossRef

  45. 45
    A. Alberti, L. Benvegnù, S. Boccato, A. Ferrari, G. Sebastiani, Natural history of initially mild chronic hepatitis C, Digestive and Liver Disease, 2004, 36, 10, 646

    CrossRef

  46. 46
    M. S. Campbell, K. R. Reddy, The evolving role of liver biopsy, Alimentary Pharmacology & Therapeutics, 2004, 20, 3
  47. 47
    A. Mangia, G. Spinzi, O. Vuturo, V. Pazienza, A. Iacobellis, M. Piattelli, A. Giacobbe, G. Leandro, V. Piermanni, G. Minoli, G. Montalto, A. Andriulli, Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study, Alimentary Pharmacology & Therapeutics, 2004, 19, 3
  48. 48
    Chee-Kin Hui, Tigist Belaye, Kevin Montegrande, Teresa Lyn Wright, A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase, Journal of Hepatology, 2003, 38, 4, 511

    CrossRef

  49. 49
    Daniel Sussman, Jamie S. Barkin, Band ligation versus propanolol and isosorbide mononitrate for primary prophylaxis of variceal bleeding. Lui HF, Stanley AJ, Forrest EH, et al., Primary Prophylaxis of Variceal Hemorrhage: A Randomized Controlled Trial Comparing Band Ligation, Propanolol, and Isosorbide Mononitrate.Gastroenterology 2002;123:735-44, The American Journal of Gastroenterology, 2003, 98, 8, 1887

    CrossRef

  50. 50
    Patrick Marcellin, Nathalie Boyer, Chronic viral hepatitis, Best Practice & Research Clinical Gastroenterology, 2003, 17, 2, 259

    CrossRef

  51. 51
    Claudio Puoti, HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy, Journal of Hepatology, 2003, 38, 4, 529

    CrossRef

  52. 52
    Masanori Furutani, Toshiaki Nakashima, Yoshio Sumida, Akihisa Hirohama, Takaharu Yoh, Yuko Kakisaka, Hironori Mitsuyoshi, Hiroshi Senmaru, Takeshi Okanoue, Insulin resistance/β-cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection, Liver International, 2003, 23, 4
  53. 53
    Mark W. Russo, Robert S. Brown, Patients with chronic hepatitis C who have normal ALT: A role for interferon-based therapy?, Current Hepatitis Reports, 2003, 2, 1, 11

    CrossRef

  54. 54
    Claudia O Zein, Nizar N Zein, Advances in therapy for hepatitis C infection, Microbes and Infection, 2002, 4, 12, 1237

    CrossRef

  55. 55
    Christophe Renou, Stanislas Pol, Philippe Halfon, Sophie Caillat-Zucman, Controversies about the histological features of chronic HCV patients with persistently normal alanine transaminase levels: What can be done about the present definition?, Gastroenterology, 2002, 123, 5, 1748

    CrossRef

  56. 56
    Claudio Puoti, Roberto Castellacci, Fabrizio Montagnese, Serena Zaltron, Gianfranca Stornaiuolo, Nicoletta Bergami, Lia Bellis, Davide F Precone, Paolo Corvisieri, Massimo Puoti, Eliseo Minola, Giovanni Battista Gaeta, Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC), Journal of Hepatology, 2002, 37, 1, 117

    CrossRef

  57. 57
    T. Asselah, M. Martinot, D. Cazals-Hatem, N. Boyer, A. Auperin, V. Le Breton, S. Erlinger, C. Degott, D. Valla, P. Marcellin, Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels, Journal of Viral Hepatitis, 2002, 9, 1
  58. 58
    Nicholas C. Tassopoulos, Irene Vafiadis, Dimitrios Tsantoulas, Julia Syrokosta, Gregory Hatzis, Johanna K. Delladetsima, Maria Demonakou, Vana Sypsa, Angelos E. Hatzakis, IFN-α2b Monotherapy in Patients with Chronic Hepatitis C and Persistently Normal or Near Normal Aminotransferase Activity: A Randomized, Controlled Study, Journal of Interferon & Cytokine Research, 2002, 22, 3, 365

    CrossRef

  59. 59
    Ricard Solá, Eva Cruz de Castro, Manuela Hombrados, Ramón Planas, Susanna Coll, Rosend Jardí, Jordi Sunyer, Maria Isabel Covas, Jaume Marrugat, Prevalencia de las hepatitis B y C en diversas comarcas de Cataluña: estudio transversal, Medicina Clínica, 2002, 119, 3, 90

    CrossRef

  60. 60
    Darko Nozic, Gorana Stamenkovic, Ivanko Bojic, Jovan Dimitrijevic, Ljubisa Krstic, The role of different virus genotypes in progression of chronic hepatitis C, Vojnosanitetski pregled, 2002, 59, 2, 141

    CrossRef

  61. 61
    Bruce R. Bacon, Treatment of patients with hepatitis C and normal serum aminotransferase levels, Hepatology, 2002, 36, S1
  62. 62
    F Caprioli, R Pometta, S Visentin, S Massironi, D Conte, “Hepatitic flare”, asthenia, peripheral polyneuropathy and diffuse liver steatosis in a hepatitis C virus asymptomatic chronic carrier, Digestive and Liver Disease, 2001, 33, 4, 359

    CrossRef

  63. 63
    Sophie Herv??, Guillaume Savoye, Ghassan Riachi, Marie-France Hellot, Odile Goria, Eric Lerebours, Raymond Colin, Philippe Ducrotte, Chronic hepatitis C with normal or abnormal aminotransferase levels: is it the same entity?, European Journal of Gastroenterology & Hepatology, 2001, 13, 5, 495

    CrossRef

  64. 64
    George K. Koukoulis, Chronic hepatitis C: Grading, staging, and searching for reliable predictors of outcome, Human Pathology, 2001, 32, 9, 899

    CrossRef

  65. 65
    Mark W. Russo, Robert S. Brown, Should patients with chronic hepatitis c who have normal alt levels be treated?, Current Gastroenterology Reports, 2001, 3, 1, 49

    CrossRef

  66. 66
    Pierre-Edouard Queneau, Florence Osaer, Jean-Pierre Bronowicki, Benedicte Monnot, Gerard Thiefin, Dominique Bettinger, Jean-Pierre Carbillet, Jean-Jacques Raabe, Serge Fratte, Anne Minello-Franza, Solange Bresson-Hadni, Jean-Philippe Miguet, Treatment of mild chronic hepatitis C with interferon ??-2b: results of a multi-centre randomized study in 80 patients, European Journal of Gastroenterology & Hepatology, 2001, 13, 2, 143

    CrossRef

  67. 67
    Ke-Qin Hu, John M. Vierling, Allan G. Redeker, Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, Journal of Viral Hepatitis, 2001, 8, 1, 1

    CrossRef

  68. 68
    Ke-Qin Hu, John M. Vierling, Allan G. Redeker, Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, Journal of Viral Hepatitis, 2001, 8, 1
  69. 69
    Ming-Yang Lai, Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy, Journal of Gastroenterology and Hepatology, 2000, 15,
  70. 70
    Catherine Petruff Cheney, Sanjiv Chopra, Camilla Graham, HEPATITIS C, Infectious Disease Clinics of North America, 2000, 14, 3, 633

    CrossRef

  71. 71
    C. Puoti, R. Castellacci, F. Montagnese, Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?, Digestive and Liver Disease, 2000, 32, 7, 634

    CrossRef

  72. 72
    Bernd Kronenberger, Brigitte Rüster, Jung-Hun Lee, Christoph Sarrazin, W.Kurt Roth, Günter Herrmann, Stefan Zeuzem, Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels, Journal of Hepatology, 2000, 33, 4, 640

    CrossRef

  73. 73
    P. Miailhes, C. Trépo, L'histoire naturelle de l'infection par le virus de l'hépatite c, Médecine et Maladies Infectieuses, 2000, 30, S8

    CrossRef

  74. 74
    Nathalie Boyer, Patrick Marcellin, Pathogenesis, diagnosis and management of hepatitis C, Journal of Hepatology, 2000, 32, 98

    CrossRef

  75. 75
    Michael Robert Lövy, Gordon Starkebaum, Rheumatic disorders associated with hepatitis C, Best Practice & Research Clinical Rheumatology, 2000, 14, 3, 535

    CrossRef

  76. 76
    Prati, Zanella, Zanuso, Vianello, E. Della Torre, Mozzi, Carriero, Zahm, Donato, Colombo, Sirchia, Sustained response to interferon-α2a monotherapy of young blood donors with minimal-to-mild chronic hepatitis C, Journal of Viral Hepatitis, 2000, 7, 5
    Direct Link:
  77. 77
    G.R Foster, H.C Thomas, Therapeutic options for HCV—management of the infected individual, Best Practice & Research Clinical Gastroenterology, 2000, 14, 2, 255

    CrossRef

  78. 78
    O. Lo Iacono, M. Fernández Bermejo, Tratamiento de las hepatitis crónicas víricas, Medicine - Programa de Formación Médica Continuada Acreditado, 2000, 8, 13, 686

    CrossRef

  79. 79
    John G. McHutchison, Jay H. Hoofnagle, Hepatitis C, 2000,

    CrossRef

  80. 80
    Thomas V. Inglesby, Rudra Rai, Jacquie Astemborski, Leslie Gruskin, Kenrad E. Nelson, David Vlahov, David L. Thomas, A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use, Hepatology, 1999, 29, 2
  81. 81
    Shiv K. Sarin, Gurwant S. Lamba, Mandhir Kumar, Alok Misra, Nandagudi S. Murthy, Comparison of Endoscopic Ligation and Propranolol for the Primary Prevention of Variceal Bleeding, New England Journal of Medicine, 1999, 340, 13, 988

    CrossRef

  82. 82
    Thomas M. Shehab, Seema S. Sonnad, Mark Jeffries, Naresh Gunaratnum, Anna S. Lok, Current practice patterns of primary care physicians in the management of patients with hepatitis C, Hepatology, 1999, 30, 3
  83. 83
    Francesco Negro, Krzysztof Krawczynski, Rafael Quadri, Laura Rubbia-Brandt, Mario Mondelli, Jean-Pierre Zarski, Antoine Hadengue, Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reversetranscriptase polymerase chain reaction, Hepatology, 1999, 29, 2
  84. 84
    M. Hadchouel, Faut-il traiter par l'interféron les enfants atteints d'hépatite chronique C?, Archives de Pédiatrie, 1999, 6, S178

    CrossRef

  85. 85
    Patrick Marcellin, Hepatitis C: the clinical spectrum of the disease, Journal of Hepatology, 1999, 31, 9

    CrossRef

  86. 86
    Adamowicz-Salach, Pawelec, Łoch, Zdziebłowska-Pawińska, Brojer, Walewska-Zielecka, Rokicka-Milewska, Incidence and treatment of hepatitis C virus infection in children with haemophilia in Poland, Haemophilia, 1999, 5, 6
  87. 87
    Aijaz Ahmed, Emmet B. Keeffe, OVERVIEW OF INTERFERON THERAPY FOR CHRONIC HEPATITIS C, Clinics in Liver Disease, 1999, 3, 4, 757

    CrossRef

  88. 88
    Eleanor Barnes, George Webster, Simon Whalley, Geoffrey Dusheiko, PREDICTORS OF A FAVORABLE RESPONSE TO ALPHA INTERFERON THERAPY FOR HEPATITIS C, Clinics in Liver Disease, 1999, 3, 4, 775

    CrossRef

  89. 89
    R. Christopher Benyon, Christopher J. Hovell, Marianna Da Gaça, Emma H. Jones, John P. Iredale, Michael J. P. Arthur, Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation, Hepatology, 1999, 30, 4
  90. 90
    Claudio Puoti, Tonino Stati, Andrea Magrini, Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels, Liver, 1999, 19, 2
  91. 91
    Regino P González-Peralta, George J Galasso, Thierry Poynard, Solko Schalm, Howard C Thomas, Teresa L Wright, Summary of the first international symposium on viral hepatitis, Antiviral Research, 1999, 42, 2, 77

    CrossRef

  92. 92
    C. Silvain, Traitements antiviraux de l’infection par le virus de l’hépatite C, La Revue de Médecine Interne, 1999, 20, 331s

    CrossRef

  93. 93
    Nicholas C. Tassopoulos, Treatment of patients with chronic hepatitis C and normal ALT levels, Journal of Hepatology, 1999, 31, 193

    CrossRef

  94. 94
    Aijaz Ahmed, Emmet Keeffe, Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health Consensus Development Conference, Journal of Gastroenterology and Hepatology, 1999, 14, 5s
  95. 95
    Angelo Sangiovanni, Rino Morales, GianCarlo Spinzi, MariaGrazia Rumi, Antonietta Casiraghi, Roberto Ceriani, Enrico Colombo, Maurizio Fossati, Alberto Prada, Enrico Tavani, Giorgio Minoli, Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study, Hepatology, 1998, 27, 3